Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Retrotope’s RT001 improves cognition in Huntington’s model
September 2018
SHARING OPTIONS:

LOS ANGELES & LOS ALTOS, Calif.—A recent paper in The FEBS Journal has detailed how Retrotope’s D-PUFA drug candidate, RT001, can reduce cognitive deficits in a preclinical in-vivo model of Huntington’s disease and downregulate brain lipid peroxidation biomarkers. The paper was published by Retrotope and collaborators led by Dr. Marie-Francoise Chesselet, the Charles H. Markham Professor of Neurology and interim chair of the Department of Neurology at UCLA. RT001 is a deuterated polyunsaturated fatty acid (D-PUFA) drug candidate, a type of therapeutic that can ““fireproof” mitochondrial and cellular membranes against attack and restore cellular health,” according to Retrotope. When taken together with previous preclinical and clinical results for this class of therapeutics, Retrotope believes these results support the notion of D-PUFA drugs as “a disease-modifying therapy for multiple intractable neurodegenerative diseases.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.